In Ewing sarcoma cell lines and patient-derived xenograft (PDX) lines, AKT pathway activation protects Ewing sarcoma cells against BRD4 inhibitors, and IGF1R inhibitors and mTOR inhibitors suppress AKT pathway activation and synergistically enhance cancer cell sensitivity to BRD4 inhibitors [53]. The gene discussed is MTOR; the disease is Ewing sarcoma.